Amicus Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 517
- Market Cap
- $3.3B
- Website
- http://www.amicusrx.com
- Introduction
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.
Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU
Alnylam Pharmaceuticals submitted a Type II Variation to the European Medicines Agency for vutrisiran, an RNAi therapeutic for ATTR amyloidosis with cardiomyopathy, supported by positive phase III HELIOS-B study results. The company already markets vutrisiran in the EU as Amvuttra for hATTR amyloidosis. If approved, vutrisiran could become the new standard of care for ATTR-CM, expanding the eligible patient population and driving growth.
Pompe Disease Clinical Trials 2024 (Updates): EMA, PDMA, FDA
DelveInsight's 'Pompe Disease Pipeline Insights, 2024' covers 15+ companies and 20+ pipeline drugs, including clinical and nonclinical stage products. Key companies include Spark Therapeutics, Amicus Therapeutics, and Asklepios Biopharmaceutical. Recent updates include study results from Astellas Gene Therapies, Amicus Therapeutics, and Genzyme. Pompe disease is a rare genetic disorder with treatments like enzyme replacement therapy.
© Copyright 2024. All Rights Reserved by MedPath